The defendant marketed its patented drug for the treatment of epilepsy, generalised anxiety disorder and neuropathic pain under the protection of a European patent. The claimants now challenged the renewal of the patent for obviousness.
Held: There was sufficient disclosure in the specification to support the claim that pregabalin was efficacious in the treatment of inflammatory pain and peripheral neuropathic pain, but not central neuropathic pain.
Arnold J
[2015] EWHC 2548 (Pat), [2015] CN 1499, [2016] RPC 3
Bailii
England and Wales
Cited by:
At First Instance (Patents Court) – Warner-Lambert Company Llc v Generics (UK) Ltd (T/A Mylan) and Another SC 14-Nov-2018
These proceedings raise, for the first time in the courts of the United Kingdom, the question how the concepts of sufficiency and infringement are to be applied to a patent relating to a specified medical use of a known pharmaceutical compound. . .
Lists of cited by and citing cases may be incomplete.
Updated: 12 October 2021; Ref: scu.552799
